Yes, but so will everyone else. By that point the window for buying in at a cheap price closes rapidly.
It's simply a matter of risk tolerance. To some, it's better to risk a fixed amount that could go to zero but could have exponential gain. To others, it's better to risk a fixed amount that will most likely lose only a small fraction of its value, but has a lower ceiling for profit. You appear to fall into the latter category. Nothing wrong with that.
I put the odds closer to 50/50, but my gut tells me that it's probably closer to 70/30 that Blarcamesine is approved. My gut also misleads me all the time. I think the most recent data that shows long term time-saved for 71% of the population pushes it over the edge. If it had a less favorable safety record and didn't have precision medicine biomarker data, I'd be more cautious about the EMA giving the green light. But there is an actual need for something that works upstream and all of Anavex's corporate actions appear in line with a company that is looking to the business development side at this point in its history.
Market Data 
Markets 
AI
